Risk factors for potential drug-drug interactions in intensive care unit patients

Janković, Slobodan M.; Pejčić, Ana V; Milosavljević, Miloš N.; Opančina, Valentina; Pešić, Nikola V.; Nedeljkovic, T.; Babić, Goran

doi:10.1016/j.jcrc.2017.08.021

Cited by 57 publications

(58 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sample size varied from 44 to 1510, totalling 9577 patients. The majority of papers were cross sectional and from developing countries: 9 studies were from Brazil,27–35 6 studies were from India,36–41 2 from Mexico,42 43 2 from Croatia,44 45 1 from Venezuela,46 1 from Serbia,47 1 from Nepal,48 1 from Iran49 and one from Ethiopia 50. The remaining 10 studies were from Spain,51 52 Norway,53 Portugal,54 Germany,55 Italy,56 Austria,57 Israel,58 Canada15 and Australia 59.…”

Section: Resultsmentioning

confidence: 99%

Prevalence of drug interactions in hospitalised elderly patients: a systematic review

et al. 2020

View full text Add to dashboard Cite

BackgroundThe prevalence of drug–drug interactions (DDIs) in hospital settings is variable, and elderly patients are considered a high risk population for DDIs. There are no systematic reviews describing the prevalence of DDIs in hospitalised elderly patients.ObjectivesTo assess and summarise the available data on the prevalence of DDIs in hospitalised elderly patients and to describe which drugs, drug classes and drug combinations are most commonly involved in DDIs.Data sourceA systematic electronic literature search was conducted on Medline/PubMed, Embase, Lilacs, SciElo, Web of Science, Cinahl, Scopus, Cochrane, OpenGrey, Capes Thesis Bank, OasisBR, OpenAire and abstracts from scientific events, without limitation on language or period of publication. Study selection was completed on 21 September 2018.Study eligibility criteria, participants and interventionsOriginal observational studies that reported the prevalence of actual or potential DDIs during hospitalisation in patients aged 60 years or older were included. The main outcome measure was prevalence of DDIs and number of DDIs per patient. Subgroup analysis was performed in studies that reported the prevalence of DDIs in geriatric units.Study appraisal and synthesis methodsStudy quality was assessed using the Agency for Healthcare Research and Quality methodological checklist for cross sectional and prevalence studies.Results34 studies were included, involving 9577 patients. The prevalence of DDIs ranged from 8.34% to 100%. In studies conducted in geriatric units, the prevalence ranged from 80.5% to 90.5%. The number of DDIs per patient ranged from 1.2 to 30.6. Single drugs most commonly involved in DDIs were furosemide, captopril, warfarin and dipyrone. Drug classes mostly involved were potassium sparing diuretics and angiotensin converting enzyme inhibitors.LimitationsThe main limitation is the heterogeneity between the included studies that precluded a meta-analysis. Several different methods were used to identify DDIs, majorly, and potential DDIs. Few studies have reported measures to control the quality of the collected data.Conclusions and implications of key findingsThe prevalence of DDIs ranged widely, and the variation may reflect differences in the conditions of the elderly patients and level of attention (or complexity of care), as well as methodological differences, especially the methods and/or software used to identify DDIs.Systematic review registration numberCRD42018096720

show abstract

Section: Resultsmentioning

confidence: 99%

Prevalence of drug interactions in hospitalised elderly patients: a systematic review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…DDIs are also more frequent in hospitalized patients, patients who stay in the hospital for a longer time, and/or receive more drugs per day [13,[14][15][16]. Hospitalized patients are more likely to be affected by DDIs because of severe and multiple illnesses, comorbid conditions, chronic therapeutic regimens, poly-pharmacy, and frequent modi cation in therapy [17].…”

Section: Introductionmentioning

confidence: 99%

Prevalence of potential drug- drug interactions and associated factors among outpatients and inpatients in Ethiopian Hospitals: a systematic review and Meta-analysis of observational studies

Ayenew

Asmamaw

Issa

2020

Preprint

View full text Add to dashboard Cite

Background: Drug-drug interaction is an emerging threat to public health. Currently, there is an increase in comorbid disease, polypharmacy, and hospitalization in Ethiopia. Thus, the possibility of drug-drug interaction occurrence is high in hospitals. This study aims to summarize the prevalence of potential drug-drug interactions and associated factors in Ethiopian hospitals.Methods: A literature search was performed by accessing legitimate databases in PubMed/MEDLINE, Google Scholar, and Research Gate for English-language publications. To fetch further related topics advanced search was also applied in Science Direct and HINARI databases. The search was conducted on August 3 to 25, 2019. All published articles available online until the day of data collection were considered. Outcome measures were analyzed with Open Meta Analyst and CMA version statistical software. Der Simonian and Laird’s random effect model, I2 statistics, and Logit event rate were also performed.Results: A total of 14 studies remained eligible for inclusion in systematic review and meta-analysis. From the included studies, around 8,717 potential drug-drug interactions were found in 3,259 peoples out of 5,761 patients. The prevalence of patients with potential drug-drug interactions in Ethiopian hospitals was found to be 72.2% (95% confidence interval: 59.1%, 85.3%). Based on severity, the prevalence of major, moderate, and minor potential drug-drug interaction was 25.1%, 52.8%, 16.9%, respectively, also 1.27% for contraindications. The factors associated with potential drug-drug interactions were related to patient characteristics such as polypharmacy, age, comorbid disease, and hospital stay.Conclusions: There is a high prevalence of potential drug-drug interactions in Ethiopian hospitals. Polypharmacy, age, comorbid disease, and hospital stay were the risk factors associated with potential drug-drug interactions.

show abstract

“…Drug-drug interactions (DDIs) are defined as a medication interferes with pharmacokinetic, pharmacodynamic, or pharmaceutical properties of another drug, resulting in an altered net effect of one or both drugs (1). DDIs could be a significant cause of morbidity and mortality because they may result in enhancement of drug toxicity and decrease in therapeutic effects of drugs (2)(3)(4). DDIs are of particular concern in oncology be-cause anticancer drugs usually have a narrow therapeutic index and small changes in cytotoxic activity due to a DDI can have serious consequences (5).…”

Section: Introductionmentioning

confidence: 99%

The Prevalence of the Potential Drug-Drug Interactions Involving Anticancer Drugs in China: A Retrospective Study

Wang¹,

Xiao²,

Liu³

et al. 2019

ijph

View full text Add to dashboard Cite

Background: To survey the prevalence of potential drug-drug interactions (DDIs) between anticancer drugs and non-anticancer drugs and evaluate the risk factors associated with these drug-drug interactions in China. Methods: All discharged patients in the Department of Oncology were collected from Jun to Dec in 2016 with the Hospital Information System of the Chinese people’s Liberation Army General Hospital. Drugs were screened for interactions by Micromedex solutions database. Descriptive statistics were generated and logistic regression was used to identify the associated factors. Results: Among 6578 eligible patients, 1979 potential drug interactions were found in 1830 patients (27.82%). The most common drug-drug interaction was cisplatin and furosemide. Erlotinib was most likely to interact with various non-anticancer drugs. Most interactions were classified as pharmacodynamics (71.60%), major severity (97.02%) and were supported by fair documentation evidence (86.21%). In multivariate analysis, increasing number of medications, lung cancer and patients with stage IV had a higher risk for potential drug-drug interactions. Conclusion: Potential drug-drug interactions between antineoplastic drugs and non-antineoplastic drugs occur frequently in cancer patients of Chinese hospitals. Doctors should fully consider potential risk associated with DDIs. Further research should be performed to evaluate real clinical significance of these drug-drug interactions.

show abstract

Risk factors for potential drug-drug interactions in intensive care unit patients

Cited by 57 publications

References 28 publications

Prevalence of drug interactions in hospitalised elderly patients: a systematic review

Prevalence of drug interactions in hospitalised elderly patients: a systematic review

Prevalence of potential drug- drug interactions and associated factors among outpatients and inpatients in Ethiopian Hospitals: a systematic review and Meta-analysis of observational studies

The Prevalence of the Potential Drug-Drug Interactions Involving Anticancer Drugs in China: A Retrospective Study

Contact Info

Product

Resources

About